Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 152
Filtrar
2.
Mol Psychiatry ; 22(9): 1345-1351, 2017 09.
Artigo em Inglês | MEDLINE | ID: mdl-27240527

RESUMO

The single-nucleotide polymorphism rs9804190 in the Ankyrin G (ANK3) gene has been reported in genome-wide association studies to be associated with bipolar disorder (BD). However, the neural system effects of rs9804190 in BD are not known. We investigated associations between rs9804190 and gray and white matter (GM and WM, respectively) structure within a frontotemporal neural system implicated in BD. A total of 187 adolescent and adult European Americans were studied: a group homozygous for the C allele (52 individuals with BD and 56 controls) and a T-carrier group, carrying the high-risk T allele (38 BD and 41 controls). Subjects participated in high-resolution structural magnetic resonance imaging and diffusion tensor imaging (DTI) scanning. Frontotemporal region of interest (ROI) and whole-brain exploratory analyses were conducted. DTI ROI-based analysis revealed a significant diagnosis by genotype interaction within the uncinate fasciculus (P⩽0.05), with BD subjects carrying the T (risk) allele showing decreased fractional anisotropy compared with other subgroups, independent of age. Genotype effects were not observed in frontotemporal GM volume. These findings support effects of rs9804190 on frontotemporal WM in adolescents and adults with BD and suggest a mechanism contributing to WM pathology in BD.


Assuntos
Anquirinas/genética , Transtorno Bipolar/genética , Transtorno Bipolar/patologia , Substância Cinzenta/patologia , Substância Branca/patologia , Adolescente , Adulto , Anquirinas/metabolismo , Transtorno Bipolar/diagnóstico por imagem , Transtorno Bipolar/metabolismo , Encéfalo/diagnóstico por imagem , Encéfalo/patologia , Imagem de Tensor de Difusão , Feminino , Frequência do Gene , Estudo de Associação Genômica Ampla , Substância Cinzenta/diagnóstico por imagem , Substância Cinzenta/metabolismo , Humanos , Imageamento por Ressonância Magnética/métodos , Masculino , Rede Nervosa/diagnóstico por imagem , Rede Nervosa/patologia , Polimorfismo de Nucleotídeo Único , Fatores de Risco , Substância Branca/diagnóstico por imagem , Substância Branca/metabolismo
3.
Neuroscience ; 274: 44-52, 2014 Aug 22.
Artigo em Inglês | MEDLINE | ID: mdl-24853053

RESUMO

ß-Site amyloid precursor protein cleaving enzyme (BACE1) is the rate-limiting enzyme for production of Aß peptides, proposed to drive the pathological changes found in Alzheimer's disease (AD). Reticulon 3 (RTN3) is a negative modulator of BACE1 (ß-secretase) proteolytic activity, while peptidylprolyl isomerase (cyclophilin)-like 2 (PPIL2) positively regulated BACE1 gene expression in a cell-based assay. This study aimed to analyze RTN3 and PPIL2 mRNA levels in four brain regions from individuals with AD and controls. BACE1 mRNA had been previously quantified in the samples, as had glial fibrillary acidic protein (GFAP) and neuron-specific enolase (NSE), to track changing cell populations in the tissue. mRNA levels in the human post mortem brain tissue were assayed using quantitative real-time polymerase chain reaction (qPCR) and qbase(PLUS), employing validated stably expressed reference genes. No differences in RTN3 or PPIL2 mRNA levels were found in individuals with AD, compared to controls. Both RTN3 and PPIL2 mRNA levels correlated significantly with BACE1 mRNA and all three showed similar disease stage-dependent changes with respect to NSE and GFAP. These findings indicated that the in vitro data demonstrating an effect of PPIL2 on BACE1 expression have functional relevance in vivo. Further research into BACE1-interacting proteins could provide a fruitful approach to the modulation of this protease and consequently Aß production.


Assuntos
Doença de Alzheimer/metabolismo , Secretases da Proteína Precursora do Amiloide/análise , Ácido Aspártico Endopeptidases/análise , Encéfalo/metabolismo , Proteínas de Transporte/análise , Ciclofilinas/análise , Proteínas de Membrana/análise , Proteínas do Tecido Nervoso/análise , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , RNA Mensageiro/análise
4.
Nat Genet ; 45(12): 1452-8, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-24162737

RESUMO

Eleven susceptibility loci for late-onset Alzheimer's disease (LOAD) were identified by previous studies; however, a large portion of the genetic risk for this disease remains unexplained. We conducted a large, two-stage meta-analysis of genome-wide association studies (GWAS) in individuals of European ancestry. In stage 1, we used genotyped and imputed data (7,055,881 SNPs) to perform meta-analysis on 4 previously published GWAS data sets consisting of 17,008 Alzheimer's disease cases and 37,154 controls. In stage 2, 11,632 SNPs were genotyped and tested for association in an independent set of 8,572 Alzheimer's disease cases and 11,312 controls. In addition to the APOE locus (encoding apolipoprotein E), 19 loci reached genome-wide significance (P < 5 × 10(-8)) in the combined stage 1 and stage 2 analysis, of which 11 are newly associated with Alzheimer's disease.


Assuntos
Doença de Alzheimer/genética , Loci Gênicos , Predisposição Genética para Doença , Estudo de Associação Genômica Ampla/estatística & dados numéricos , Idade de Início , Idoso , Idoso de 80 Anos ou mais , Doença de Alzheimer/epidemiologia , Estudos de Casos e Controles , Estudos de Coortes , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Polimorfismo de Nucleotídeo Único
5.
Nat Commun ; 4: 1982, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23770887

RESUMO

Parkin is a RING-between-RING E3 ligase that functions in the covalent attachment of ubiquitin to specific substrates, and mutations in Parkin are linked to Parkinson's disease, cancer and mycobacterial infection. The RING-between-RING family of E3 ligases are suggested to function with a canonical RING domain and a catalytic cysteine residue usually restricted to HECT E3 ligases, thus termed 'RING/HECT hybrid' enzymes. Here we present the 1.58 Å structure of Parkin-R0RBR, revealing the fold architecture for the four RING domains, and several unpredicted interfaces. Examination of the Parkin active site suggests a catalytic network consisting of C431 and H433. In cells, mutation of C431 eliminates Parkin-catalysed degradation of mitochondria, and capture of an ubiquitin oxyester confirms C431 as Parkin's cellular active site. Our data confirm that Parkin is a RING/HECT hybrid, and provide the first crystal structure of an RING-between-RING E3 ligase at atomic resolution, providing insight into this disease-related protein.


Assuntos
Ubiquitina-Proteína Ligases/química , Ubiquitina-Proteína Ligases/metabolismo , Biocatálise , Domínio Catalítico , Humanos , Mitocôndrias/metabolismo , Modelos Moleculares , Mutação , Doença de Parkinson/enzimologia , Doença de Parkinson/genética , Fenilalanina , Estrutura Terciária de Proteína
6.
J Neurol ; 259(12): 2761-3, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23161458
7.
J Neurol Neurosurg Psychiatry ; 83(3): 336-8, 2012 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-22147072

RESUMO

Generalised epilepsy with febrile seizures plus (GEFS+) is the most studied familial epilepsy syndrome. However, characteristics of UK families have not previously been reported. Among the first 80 families recruited to our families study, four broad subphenotypes were identified: families with classical GEFS+; families with borderline GEFS+; families with unclassified epilepsy; and families with an alternative syndromal diagnosis. Borderline GEFS+ families shared many characteristics of classical GEFS+ families-such as prominent febrile seizures plus and early onset febrile seizures-but included more adults with focal epilepsies (rather than the idiopathic generalised epilepsies predominating in GEFS+) and double the prevalence of migraine. Thus the authors believe that a novel and robust familial epilepsy phenotype has been identified. Subcategorising families with epilepsy is helpful in targeting both clinical and research resources. Most families with GEFS+ have no identified causal mutation, and so predicting genetic homogeneity by identifying endophenotypes becomes more important.


Assuntos
Epilepsia Generalizada/classificação , Convulsões Febris/classificação , Epilepsia Generalizada/diagnóstico , Epilepsia Generalizada/genética , Epilepsia Generalizada/patologia , Humanos , Transtornos de Enxaqueca/genética , Transtornos de Enxaqueca/patologia , Linhagem , Fenótipo , Convulsões Febris/diagnóstico , Convulsões Febris/genética , Convulsões Febris/patologia , Síndrome
8.
Br J Cancer ; 105(10): 1487-94, 2011 Nov 08.
Artigo em Inglês | MEDLINE | ID: mdl-21989182

RESUMO

BACKGROUND: The aim of this pilot retrospective study was to investigate the immunohistochemical expression of Cathepsin S (CatS) in three cohorts of colorectal cancer (CRC) patients (n=560). METHODS: Prevalence and association with histopathological variables were assessed across all cohorts. Association with clinical outcomes was investigated in the Northern Ireland Adjuvant Chemotherapy Trial cohort (n=211), where stage II/III CRC patients were randomised between surgery-alone or surgery with adjuvant fluorouracil/folinic acid (FU/FA) treatment. RESULTS: Greater than 95% of tumours had detectable CatS expression with significantly increased staining in tumours compared with matched normal colon (P>0.001). Increasing CatS was associated with reduced recurrence-free survival (RFS; P=0.03) among patients treated with surgery alone. Adjuvant FU/FA significantly improved RFS (hazard ratio (HR), 0.33; 95% CI, 0.12-0.89) and overall survival (OS; HR, 0.25; 95% CI, 0.08-0.81) among 36 patients with high CatS. Treatment did not benefit the 66 patients with low CatS, with a RFS HR of 1.34 (95% CI, 0.60-3.19) and OS HR of 1.33 (95% CI, 0.56-3.15). Interaction between CatS and treatment status was significant for RFS (P=0.02) and OS (P=0.04) in a multivariate model adjusted for known prognostic markers. CONCLUSION: These results signify that CatS may be an important prognostic biomarker and predictive of response to adjuvant FU/FA in CRC.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Biomarcadores Tumorais/metabolismo , Catepsinas/metabolismo , Quimioterapia Adjuvante , Neoplasias Colorretais/tratamento farmacológico , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos de Coortes , Neoplasias Colorretais/enzimologia , Neoplasias Colorretais/cirurgia , Feminino , Fluoruracila/administração & dosagem , Humanos , Imuno-Histoquímica , Leucovorina/administração & dosagem , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Prognóstico
9.
Osteoporos Int ; 22(2): 551-7, 2011 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20798929

RESUMO

UNLABELLED: Adherence to, and persistence with, treatments for osteoporosis are low. Adherence with teriparatide decreases over time. Higher copayments in the commercial/Medicare population were associated with worse persistence. Understanding factors such as prior screening, prior treatment history, and out of pocket costs that influence persistence with teriparatide may help clinicians make informed decisions. INTRODUCTION: The purpose of this study was to evaluate adherence and persistence with teriparatide. METHODS: Beneficiaries with at least one claim for teriparatide in 2003 or 2004 and continuous enrollment in the previous 12 months and subsequent 6 months were identified in a national commercial/Medicare and Medicaid administrative claims database (MarketScan®). Adherence was assessed through calculation of the medication possession ratio (MPR). Persistence was measured by time until discontinuation and time until first 60-day gap in treatment. Factors associated with persistence were assessed using Cox proportional hazards models. RESULTS: The average MPR at 6 months was 0.74 (N=2,218) and at 12 months, was 0.66 (N=1,303). At 6 months, 64.6% of patients remained on therapy and at 12 months, 56.7% remained. Bone mineral density screening and use of antiresorptive therapy within the 12 months pre-period, and lower patient copayments were associated with increased persistence. CONCLUSION: Patients appear to have good adherence with teriparatide over the first 6 months which declines over time. Prior screening and treatment of osteoporosis and out of pocket costs appear to impact persistence. To optimize patient outcomes, clinicians should consider clinical factors that impact persistence, while healthcare decision makers should consider the negative effect of higher patient copayments on persistence.


Assuntos
Conservadores da Densidade Óssea/administração & dosagem , Medicaid/estatística & dados numéricos , Medicare/estatística & dados numéricos , Osteoporose/tratamento farmacológico , Fraturas por Osteoporose/prevenção & controle , Cooperação do Paciente/estatística & dados numéricos , Teriparatida/administração & dosagem , Idoso , Idoso de 80 Anos ou mais , Conservadores da Densidade Óssea/economia , Custo Compartilhado de Seguro , Feminino , Humanos , Seguro Saúde/economia , Masculino , Pessoa de Meia-Idade , Osteoporose/economia , Estudos Retrospectivos , Fatores de Risco , Teriparatida/economia , Estados Unidos
10.
J Neurol Neurosurg Psychiatry ; 81(2): 130-5, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20145025

RESUMO

Who with sleep seizures is safe to drive? Driving law is controversial; ineligibility varies between individual US states and EU countries. Current UK driving law is strongly influenced by a single-centre study from 1974 where most participants were not taking antiepileptic drugs (AEDs). However, pure sleep-related epilepsy is often fully controlled on medication, and its withdrawal can provoke awake seizures. This systematic review asked, 'What is the risk of awake seizures in pure sleep-related epilepsy?' 9885 titles were identified; 2312 were excluded (not human or adult); 40 full texts were reviewed; six papers met our inclusion criteria; each of these six studies had a different pure sleep-related epilepsy definition. Using the largest prospective study, we were able to calculate next year's awake seizure chance (treated with antiepileptic medication). This was maximal in the second year: 5.7% (95% CI 3.0 to 10.4%). European licensing bodies including the UK's Driver and Vehicle Licensing Agency broadly accept a risk of less than 20% for Group 1 licensing. However, this study excluded patients with frontal-lobe epilepsies. Furthermore, follow-up (n=160) varied from 2 to 6 years, yet new awake seizures may occur even after 10-20 years of pure sleep-related epilepsy A paucity of evidence underpins present licensing law; current rulings would be difficult to defend if legally challenged. The law may be penalising people with pure sleep-related epilepsy without increased risk of awake seizures, while failing to identify subgroups at unacceptable risk of an awake seizure at the wheel.


Assuntos
Condução de Veículo/legislação & jurisprudência , Condução de Veículo/estatística & dados numéricos , Convulsões/epidemiologia , Sono , Vigília , Acidentes de Trânsito/estatística & dados numéricos , Anticonvulsivantes/uso terapêutico , Epilepsia do Lobo Frontal/tratamento farmacológico , Epilepsia do Lobo Frontal/epidemiologia , Feminino , Humanos , Masculino , Fatores de Risco , Convulsões/tratamento farmacológico , Fatores de Tempo , Reino Unido/epidemiologia
11.
Phytopathology ; 100(1): 49-57, 2010 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-19968549

RESUMO

Caused by a complex of Fusarium species including F. culmorum, F. graminearum, and F. pseudograminearum, Fusarium crown rot (FCR) is an important cereal disease worldwide. For this study, Fusarium population dynamics were examined in spring wheat residues sampled from dryland field locations near Bozeman and Huntley, MT, using a quantitative real-time polymerase chain reaction (qPCR) Taqman assay that detects F. culmorum, F. graminearum, and F. pseudograminearum. Between August 2005 and June 2007, Fusarium populations and residue decomposition were measured eight times for standing stubble (0 to 20 cm above the soil surface), lower stem (20 to 38 cm), middle stem (38 to 66 cm), and chaff residues. Large Fusarium populations were found in stubble collected in August 2005 from F. pseudograminearum-inoculated plots. These populations declined rapidly over the next 8 months. Remnant Fusarium populations in inoculated stubble were stable relative to residue biomass from April 2006 until June 2007. These two phases of population dynamics were observed at both locations. Relative to inoculated stubble populations, Fusarium populations in other residue fractions and from noninoculated plots were small. In no case were FCR species observed aggressively colonizing noninfested residues based on qPCR data. These results suggest that Fusarium populations are unstable in the first few months after harvest and do not expand into noninfested wheat residues. Fusarium populations remaining after 8 months were stable for at least another 14 months in standing stubble providing significant inoculums for newly sown crops.


Assuntos
Fusarium/crescimento & desenvolvimento , Fusarium/genética , Doenças das Plantas/microbiologia , Triticum/microbiologia , Análise de Variância , DNA Fúngico , Reação em Cadeia da Polimerase
12.
QJM ; 102(7): 497-9, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19286890

RESUMO

The approach to epilepsy care has transformed in the last 30 years, with more and better anti-epileptic medications, improved cerebral imaging and increased surgical options. Alongside this, developments in neuroscience and molecular genetics have furthered the understanding of epileptogenesis. Future developments in pharmacogenomics hold the promise of antiepileptic drugs matched to specific genotypes. Despite this rapid progress, one-third of epilepsy patients remain refractory to medication, with their seizures impacting upon day-to-day activity, social well-being, independence, economic output and quality of life. International genome collaborations, such as HapMap and the Welcome Trust Case-Control Consortium single nucleotide polymorphism (SNP) mapping project have identified common genetic variations in diseases of major public health importance. Such genetic signposts should help to identify at-risk populations with a view to producing more effective pharmaceutical treatments. Neurological disorders, despite comprising one-fifth of UK acute medical hospital admissions, are surprisingly under-represented in these projects. Epilepsy is the commonest serious neurological disorder worldwide. Although physically, psychologically, socially and financially disabling, it rarely receives deserved attention from physicians, scientists and governmental bodies. As outlined in this article, research into epilepsy genetics presents unique challenges. These help to explain why the identification of its complex genetic traits has lagged well behind other disciplines, particularly the efforts made in neuropsychiatric disorders. Clinical beginnings must underpin any genetic understanding in epilepsy. Success in identifying genetic traits in other disorders does not make the automatic case for genome-wide screening in epilepsy, but such is a desired goal. The essential clinical approach of accurately phenotyping, diagnosing and interpreting the dynamic nature of epilepsy remains fundamental to harvesting its potential translational outcomes.


Assuntos
Anticonvulsivantes/uso terapêutico , Epilepsia/genética , Epilepsia/tratamento farmacológico , Humanos , Qualidade de Vida/psicologia , Convulsões/prevenção & controle
13.
Dev Dyn ; 238(2): 367-75, 2009 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19161224

RESUMO

LIM-homeodomain (LIM-hd) proteins form a multifunctional family of transcription factors that plays critical roles in the development of progenitor and post-mitotic cells. Considerable work has focused on what regulates their expression post-mitotically in the spinal cord. However, little is known about what regulates LIM-hd genes at earlier developmental stages. To address this question, we explored the role of fibroblast growth factor (FGF) signalling in regulating the expression of a Xenopus laevis Lhx9 orthologue (XLhx9). XLhx9 is first expressed in the eye field and hindbrain, and when FGF receptor (FGFR) activation was inhibited prior to its onset, both brain and eye field expression was diminished. However, when FGFRs were inhibited after XLhx9 onset, retinal expression remained strong and brain expression was again diminished. These data suggest that while FGF signalling initiates and maintains brain XLhx9 expression, in the eye primordium the requirement of FGFs for expression is rapidly lost.


Assuntos
Fatores de Crescimento de Fibroblastos/metabolismo , Proteínas de Homeodomínio/biossíntese , Sistema Nervoso/embriologia , Receptores de Fatores de Crescimento de Fibroblastos/metabolismo , Proteínas de Xenopus/biossíntese , Xenopus laevis/embriologia , Sequência de Aminoácidos , Animais , Encéfalo/embriologia , Encéfalo/metabolismo , Embrião não Mamífero/metabolismo , Olho/embriologia , Olho/metabolismo , Proteínas com Homeodomínio LIM , Dados de Sequência Molecular , Sistema Nervoso/metabolismo , Rombencéfalo/embriologia , Rombencéfalo/metabolismo , Transdução de Sinais/fisiologia , Fatores de Transcrição , Xenopus laevis/metabolismo
14.
Neuromolecular Med ; 10(4): 368-76, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18581272

RESUMO

Beta-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1) is a biological and positional candidate gene for Alzheimer's disease (AD). BACE1 is a protease that catalyses APP cleavage at the beta-secretase site. We evaluated all common and putatively functional polymorphisms in the genomic region encompassing BACE1 for an association with AD, and for functional effects on platelet beta-secretase activity. Tag SNPs (n = 10) derived from phase II of the International HapMap Project, and a nonsynonymous variant, were successfully genotyped in 901 Caucasian individuals from Northern Ireland using Sequenom iPLEX and TaqMan technologies. APOE genotyping was performed by PCR-RFLP. Platelet membrane beta-secretase activity was assayed in a subset of individuals (n = 311). Hardy-Weinberg equilibrium was observed for all variants. Evidence for an association with AD was observed with multi-marker haplotype analyses (P = 0.01), and with rs676134 when stratified for APOE genotype (P = 0.02), however adjusting for multiple testing negated the evidence for association of this variant with AD. chi(2) analysis of genotype and allele frequencies in cases versus controls for individual SNPs revealed no evidence for association (5% level). No genetic factors were observed that significantly influenced platelet membrane beta-secretase activity. We have selected an appropriate subset of variants suitable for comprehensive genetic investigation of the BACE1 gene. Our results suggest that common BACE1 polymorphisms and putatively functional variants have no significant influence on genetic susceptibility to AD, or platelet beta-secretase activity, in this Caucasian Northern Irish population.


Assuntos
Doença de Alzheimer/enzimologia , Doença de Alzheimer/genética , Secretases da Proteína Precursora do Amiloide/genética , Ácido Aspártico Endopeptidases/genética , Plaquetas/enzimologia , Membrana Celular/enzimologia , Predisposição Genética para Doença/genética , Idoso , Idoso de 80 Anos ou mais , Doença de Alzheimer/etnologia , Apolipoproteínas E/genética , Análise Mutacional de DNA , Feminino , Regulação Enzimológica da Expressão Gênica/genética , Marcadores Genéticos/genética , Testes Genéticos , Genótipo , Humanos , Masculino , Irlanda do Norte/epidemiologia , Polimorfismo Genético/genética , População Branca/genética
15.
Osteoporos Int ; 19(3): 373-7, 2008 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-17710352

RESUMO

UNLABELLED: The demographic and clinical characteristics of patients initiating teriparatide were compared with those of patients initiating bisphosphonates for the treatment of osteoporosis. In these samples of commercially insured, Medicare, and Medicaid patients, patients initiating teriparatide were older, in poorer health, and appeared to have more severe osteoporosis than patients initiating bisphosphonates. INTRODUCTION: The demographic and clinical characteristics of patients initiating teriparatide are compared with those of patients initiating bisphosphonates. METHODS: Beneficiaries (45 years and older) with at least one claim for teriparatide or a bisphosphonate from 2003 to 2005 and continuous enrollment in the previous 12 months and subsequent 6 months were identified from commercial, Medicare, and Medicaid administrative claims databases. Patients initiating teriparatide (commercial/Medicare (N = 2,218); Medicaid (N = 824)) were compared to patients initiating bisphosphonates (commercial/Medicare (N = 97,570); Medicaid (N = 77,526)) in terms of age, provider specialty, comorbidities, prior use of osteoporosis medications, fractures, BMD screening, health status, and resource utilization. RESULTS: Teriparatide patients were older and in poorer health than bisphosphonate patients. Approximately 38% of teriparatide patients in both groups had fractured in the pre-period compared to 16% of commercial/Medicare and 15% of Medicaid bisphosphonate patients. Teriparatide patients were more likely to have used osteoporosis medications in the pre-period (79.9% versus 32.1% (commercial/Medicare); 82.2% versus 19.6% (Medicaid)). CONCLUSIONS: In these samples of patients, those initiating teriparatide differed from those initiating bisphosphonates. Teriparatide patients were older, in poorer health, and appeared to have more severe osteoporosis than bisphosphonate patients. Comparisons of treatment outcomes should take these differences in patient characteristics into consideration.


Assuntos
Conservadores da Densidade Óssea/uso terapêutico , Osteoporose/tratamento farmacológico , Teriparatida/uso terapêutico , Fatores Etários , Idoso , Difosfonatos/uso terapêutico , Prescrições de Medicamentos/estatística & dados numéricos , Feminino , Humanos , Masculino , Medicaid , Medicare , Pessoa de Meia-Idade , Osteoporose/etnologia , Osteoporose Pós-Menopausa/tratamento farmacológico , Osteoporose Pós-Menopausa/etnologia , Estudos Retrospectivos , Índice de Gravidade de Doença , Estados Unidos/epidemiologia
16.
Neurobiol Aging ; 29(5): 661-8, 2008 May.
Artigo em Inglês | MEDLINE | ID: mdl-17174011

RESUMO

beta-Secretase activity is the rate-limiting step in Abeta peptide production from amyloid precursor protein. Abeta is a major component of Alzheimer's disease (AD) cortical amyloid plaques. beta-Secretase activity is elevated in post mortem brain tissue in AD. The current study investigated whether beta-secretase activity was also elevated in peripheral blood platelets. We developed a novel fluorimetric beta-secretase activity assay to investigate platelets isolated from individuals with AD (n=86), and age-matched controls (n=115). Platelet membrane beta-secretase activity (expressed as initial rate) varied over fourfold between individuals, raising important questions about in vivo regulation of this proteolytic activity. Nonetheless, we identified a significant 17% increase in platelet membrane beta-secretase activity in individuals with AD compared to controls (p=0.0003, unpaired t-test). Platelet membrane beta-secretase activity did not correlate with mini-mental state examination (MMSE) score in the AD group (mean MMSE=17.7, range 1-23), indicating that the increase did not occur as a secondary result of the disease process, and may even have preceded symptom onset.


Assuntos
Doença de Alzheimer/sangue , Doença de Alzheimer/enzimologia , Secretases da Proteína Precursora do Amiloide/sangue , Plaquetas/enzimologia , Idoso , Idoso de 80 Anos ou mais , Ativação Enzimática , Feminino , Humanos , Masculino
17.
J Med Genet ; 45(4): 244-8, 2008 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-18057084

RESUMO

BACKGROUND: Sporadic Alzheimer's disease (AD) is a common disabling disease of complex aetiology for which there are limited therapeutic options. We sought to investigate the role of the alpha7 nicotinic acetylcholine receptor gene (CHRNA7) in influencing risk of AD in a large population. CHRNA7 is a strong candidate gene for AD for several reasons: (1) its expression is altered differentially in the AD brain; (2) it interacts directly with beta amyloid peptide (Abeta(42)); and (3) agonist activation induces several neuroprotective pathways. METHODS: In this study we used a genetic haplotype approach to assess the contribution of common variation at the CHRNA7 locus to risk of AD. Fourteen single nucleotide polymorphisms (SNPs) were genotyped in 764 AD patients and 314 controls. RESULTS: Three blocks of high linkage disequilibrium (LD) and low haplotype diversity were identified. The block 1 TCC haplotype was significantly associated with reduced odds of AD (p = 0.001) and was independent of apolipoprotein E (APOE) status. Individual SNPs were not associated with risk for AD. CONCLUSIONS: We conclude that genetic variation in CHRNA7 influences susceptibility to AD. These results provide support for the development of alpha7nAChR agonists or modulators as potential drug treatments for AD. Further work is necessary to replicate the findings in other populations.


Assuntos
Doença de Alzheimer/genética , Receptores Nicotínicos/genética , Regiões 5' não Traduzidas , Sequência de Bases , Estudos de Casos e Controles , Cromossomos Humanos Par 15/genética , Primers do DNA/genética , Frequência do Gene , Predisposição Genética para Doença , Haplótipos , Humanos , Íntrons , Desequilíbrio de Ligação , Polimorfismo de Nucleotídeo Único , Fatores de Risco , Receptor Nicotínico de Acetilcolina alfa7
18.
Dement Geriatr Cogn Disord ; 24(6): 464-8, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17986817

RESUMO

BACKGROUND/AIMS: We have recently reported that platelet activity of the rate-limiting enzyme for beta-amyloid peptide production is elevated in established Alzheimer's disease. Laboratory investigation of the very early stages of dementia provides an opportunity to investigate pathological mechanisms before advanced disease hinders interpretation. Mild cognitive impairment (MCI) exists prior to obvious dementia, and is associated with increased risk of conversion to overt disease. METHODS: We developed and used a fluorimetric assay to quantify platelet membrane beta-secretase activity in 52 patients with MCI and 75 controls. RESULTS: Platelet membrane beta-secretase activity was 24% higher in individuals with MCI compared to controls (p = 0.001, unpaired t test with Welch correction). CONCLUSION: Elevated platelet beta-secretase activity in subjects with MCI is an area for further study in relation to the etiology and diagnosis of MCI.


Assuntos
Secretases da Proteína Precursora do Amiloide/sangue , Plaquetas/metabolismo , Transtornos Cognitivos/sangue , Transtornos Cognitivos/diagnóstico , Idoso , Encéfalo/patologia , Feminino , Humanos , Masculino , Degeneração Neural/patologia , Testes Neuropsicológicos , Curva ROC , Índice de Gravidade de Doença
19.
Curr Med Res Opin ; 23(1): 235-44, 2007 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-17207305

RESUMO

INTRODUCTION: For patients with critical conditions including severe sepsis, minimizing the time from presentation to treatment is important to improving outcomes. Understanding the factors influencing high hospital mortality and resource utilization in severe sepsis continues to interest clinicians and researchers. This study examined the associations between timing of drotrecogin alfa (activated) (DrotAA) initiation and hospital mortality, length-of-stay, and costs. METHODS: We conducted a cohort study of adult patients (N = 1179) with intensive care unit stays from November 2001 to June 2003 who received DrotAA in US hospitals with data in the Solucient ACTracker database. We defined evident severe sepsis (ESS) as concurrent antibiotic plus ventilator and/or vasopressor use. We characterized the interval between ESS and DrotAA initiation as Same-day, Next-day, or Day 2+. We compared group characteristics and created multivariate models of hospital mortality, length-of-stay, and costs. RESULTS: Forty-three percent of patients received Same-day DrotAA, 30% Next-day, and 27% Day 2+. Same-day and Next-day patients had more organ dysfunctions at ICU admission than Day 2+ patients (1.1 +/- 0.9 and 1.2 +/- 0.8 vs. 1.0 +/- 0.8; p = 0.021 and p < 0.001, respectively), but from ESS to DrotAA initiation, organ dysfunctions for Day 2+ patients had increased more (+0.0 and +0.4 vs. +0.6, respectively; all p < 0.0001). Increased mortality was observed with administration later than Same-day, although only for the Day 2+ group did the association remain significant (p < 0.05) after adjusting for clinical and demographic factors. Only Next-day initiation was associated with significantly decreased costs (p = 0.0145). CONCLUSIONS: Timing of DrotAA initiation is associated with clinical and economic outcomes in severe sepsis. The potential impact of this timing on hospital mortality, length-of-stay, and costs deserves further study.


Assuntos
Anti-Infecciosos/uso terapêutico , Custos Hospitalares/estatística & dados numéricos , Mortalidade Hospitalar , Tempo de Internação/estatística & dados numéricos , Proteína C/uso terapêutico , Sepse/tratamento farmacológico , Adolescente , Adulto , Idoso , Anti-Infecciosos/administração & dosagem , Estudos de Coortes , Bases de Dados Factuais , Feminino , Humanos , Unidades de Terapia Intensiva , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Alta do Paciente , Proteína C/administração & dosagem , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/uso terapêutico , Sepse/mortalidade , Resultado do Tratamento , Estados Unidos/epidemiologia
20.
Biochem Soc Trans ; 34(Pt 5): 764-9, 2006 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17052193

RESUMO

Ubiquitination is now accepted as an important process for regulating intracellular signalling and the realization that many known signalling molecules exhibit E3 ligase activity has led to great strides in our understanding of how these pathways are regulated. However, as most of the de-ubiquitinating enzymes have as yet no identified substrate, little is known about their potential role in the regulation of intracellular signalling. Here, we examine what is known about de-ubiquitinating enzymes and signalling, with particular emphasis on their role in the regulation of immune signalling and the initiation of DNA repair. In addition, we look at the evidence implicating these enzymes in the pathogenesis of diseases such as cancer and neurodegenerative diseases.


Assuntos
Ubiquitina-Proteína Ligases/metabolismo , Animais , Reparo do DNA , GTP Fosfo-Hidrolases/metabolismo , Humanos , Modelos Biológicos , NF-kappa B/fisiologia , Transdução de Sinais/imunologia , Transdução de Sinais/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...